Chris H. Bangma

17.6k total citations · 2 hit papers
213 papers, 9.9k citations indexed

About

Chris H. Bangma is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Chris H. Bangma has authored 213 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 167 papers in Pulmonary and Respiratory Medicine, 68 papers in Surgery and 55 papers in Oncology. Recurrent topics in Chris H. Bangma's work include Prostate Cancer Diagnosis and Treatment (151 papers), Prostate Cancer Treatment and Research (140 papers) and Bladder and Urothelial Cancer Treatments (48 papers). Chris H. Bangma is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (151 papers), Prostate Cancer Treatment and Research (140 papers) and Bladder and Urothelial Cancer Treatments (48 papers). Chris H. Bangma collaborates with scholars based in Netherlands, United States and Canada. Chris H. Bangma's co-authors include Monique J. Roobol, Fritz H. Schröder, Ewout W. Steyerberg, Roderick C.N. van den Bergh, Antti Rannikko, Theodorus van der Kwast, Ries Kranse, Xiaoye Zhu, Tineke Wolters and Mark F. Wildhagen and has published in prestigious journals such as Nature Medicine, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Chris H. Bangma

203 papers receiving 9.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study

2012 411 citations Meelan Bul, Xiaoye Zhu et al. European Urology profile →
A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment

2016 272 citations Chris H. Bangma, Monique J. Roobol et al. European Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chris H. Bangma Netherlands	56	7.1k	2.4k	2.1k	1.6k	1.3k	213	9.9k
Kevin M. Slawin United States	55	6.9k 1.0×	1.5k 0.6×	1.9k 0.9×	2.0k 1.2×	1.8k 1.4×	183	10.0k
Andrew J. Stephenson United States	51	7.7k 1.1×	3.4k 1.4×	1.2k 0.6×	1.7k 1.0×	1.7k 1.3×	242	10.5k
Edward M. Schaeffer United States	50	5.7k 0.8×	1.5k 0.6×	2.0k 1.0×	2.1k 1.3×	1.0k 0.8×	294	9.4k
Gunnar Aus Sweden	38	7.0k 1.0×	1.7k 0.7×	1.6k 0.8×	764 0.5×	1.5k 1.1×	94	8.4k
David G. McLeod United States	61	9.7k 1.4×	1.9k 0.8×	2.5k 1.2×	3.0k 1.9×	1.4k 1.1×	271	13.3k
Thomas Wiegel Germany	38	8.2k 1.2×	1.9k 0.8×	1.8k 0.9×	838 0.5×	1.6k 1.2×	232	10.5k
Armen Aprikian Canada	48	4.2k 0.6×	3.0k 1.2×	2.0k 1.0×	2.2k 1.3×	930 0.7×	279	8.7k
Todd M. Morgan United States	46	3.9k 0.6×	2.5k 1.0×	2.2k 1.1×	1.9k 1.2×	553 0.4×	307	8.3k
Paul H. Lange United States	60	7.4k 1.0×	3.5k 1.4×	2.1k 1.0×	2.9k 1.7×	2.1k 1.6×	265	12.6k
Michael K. Brawer United States	49	7.0k 1.0×	1.4k 0.6×	1.1k 0.5×	1.5k 0.9×	2.3k 1.7×	168	9.0k

Countries citing papers authored by Chris H. Bangma

Since Specialization

Citations

This map shows the geographic impact of Chris H. Bangma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris H. Bangma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris H. Bangma more than expected).

Fields of papers citing papers by Chris H. Bangma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris H. Bangma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris H. Bangma. The network helps show where Chris H. Bangma may publish in the future.

Co-authorship network of co-authors of Chris H. Bangma

This figure shows the co-authorship network connecting the top 25 collaborators of Chris H. Bangma. A scholar is included among the top collaborators of Chris H. Bangma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris H. Bangma. Chris H. Bangma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bangma, Chris H., Maarten J. Bijlsma, Alfons C.M. van den Bergh, et al.. (2025). External beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study. BMC Cancer. 25(1). 149–149. 1 indexed citations

Hemminki, Kari, Lambertus A. Kiemeney, Alicia K. Morgans, et al.. (2024). Hereditary and Familial Traits in Urological Cancers and Their Underlying Genes. European Urology Open Science. 69. 13–20. 1 indexed citations

Hollemans, Eva, Esther I. Verhoef, Chris H. Bangma, et al.. (2020). Clinicopathological characteristics of glomeruloid architecture in prostate cancer. Modern Pathology. 33(8). 1618–1625. 7 indexed citations

Verbeek, Jan, Chris H. Bangma, Charlotte F. Kweldam, et al.. (2018). Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. Urologic Oncology Seminars and Original Investigations. 37(2). 138–144. 29 indexed citations

Bruinsma, Sophie, Liying Zhang, Monique J. Roobol, et al.. (2017). The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. British Journal of Urology. 121(5). 737–744. 40 indexed citations

Kandimalla, Raju, Roy Masius, Willemien Beukers, et al.. (2013). A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine. Clinical Cancer Research. 19(17). 4760–4769. 51 indexed citations

Roobol, Monique J., Ries Kranse, Chris H. Bangma, et al.. (2013). Screening for Prostate Cancer: Results of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer. European Urology. 64(4). 530–539. 91 indexed citations

Kandimalla, Raju, Angela A.G. van Tilborg, Lucie C. Kompier, et al.. (2012). Genome-wide Analysis of CpG Island Methylation in Bladder Cancer Identified TBX2, TBX3, GATA2, and ZIC4 as pTa-Specific Prognostic Markers. European Urology. 61(6). 1245–1256. 95 indexed citations

Loeb, Stacy, et al.. (2012). Reply from Authors re: Alexandre R. Zlotta, Robert K. Nam. To Biopsy or Not to Biopsy—Thou Shall Think Twice. Eur Urol 2012;61:1115–7. European Urology. 61(6). 1117–1118. 4 indexed citations

10.

Zhu, Xiaoye, Pim J. van Leeuwen, Meelan Bul, et al.. (2011). Disease-Specific Survival of Men With Prostate Cancer Detected During the Screening Interval: Results of the European Randomized Study of Screening for Prostate Cancer–Rotterdam After 11 Years of Follow-Up. European Urology. 60(2). 330–336. 8 indexed citations

11.

Catàlona, William J., Alan W. Partin, Martin G. Sanda, et al.. (2011). A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range. The Journal of Urology. 185(5). 1650–1655. 356 indexed citations

12.

Zuiverloon, Tahlita C.M., Madelon N.M. van der Aa, Theodorus van der Kwast, et al.. (2010). Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle–Invasive Bladder Cancer. Clinical Cancer Research. 16(11). 3011–3018. 83 indexed citations

13.

Briganti, Alberto, Martin Spahn, Steven Joniau, et al.. (2010). 1013 PREDICTING FAVOURABLE PATHOLOGICAL OUTCOME IN PATIENTS WITH CLINICAL HIGH RISK PROSTATE CANCER. A NOVEL NOMOGRAM BASED ON A MULTI-INSTITUTIONAL ANALYSIS. European Urology Supplements. 9(2). 317–318.

14.

Wolters, Tineke, Monique J. Roobol, Ewout W. Steyerberg, et al.. (2009). The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. International Journal of Cancer. 126(10). 2387–2393. 51 indexed citations

15.

Wolters, Tineke, Kees J. Vissers, Chris H. Bangma, Fritz H. Schröder, & Geert J.L.H. van Leenders. (2009). The value of EZH2, p27 ^kip1 , BMI‐1 and MIB‐1 on biopsy specimens with low‐risk prostate cancer in selecting men with significant prostate cancer at prostatectomy. British Journal of Urology. 106(2). 280–286. 26 indexed citations

16.

Rhijn, Bas W.G. van, Bharati Bapat, Theodorus van der Kwast, et al.. (2009). 308 THE FGFR3 MUTATION IS RELATED TO FAVORABLE PT1 BLADDER CANCER. European Urology Supplements. 8(4). 197–197. 10 indexed citations

17.

Raaijmakers, René, Stijn H. de Vries, B. G. Blijenberg, et al.. (2007). hK2 and Free PSA, a Prognostic Combination in Predicting Minimal Prostate Cancer in Screen-Detected Men within the PSA Range 4–10 ng/ml. European Urology. 52(5). 1358–1364. 30 indexed citations

18.

Schröder, Fritz H., Claartje Gosselaar, Stijn Roemeling, et al.. (2006). PSA and the Detection of Prostate Cancer After 2005. Part II: Ways Out of the PSA Dilemma?. 4(2). 71–81. 1 indexed citations

19.

Schepers, Marieke S.J., et al.. (2005). Crystals cause acute necrotic cell death in renal proximal tubule cells, but not in collecting tubule cells. Kidney International. 68(4). 1543–1553. 85 indexed citations

20.

Bangma, Chris H. & Paul C.M.S. Verhagen. (2000). Blood and serum substances for markers of prostate cancer. Microscopy Research and Technique. 51(5). 430–435. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact